

SMALL CHANGE. BIG IMPACT.



GORE® PROPATEN®

Vascular Graft

Configured for Pediatric Shunt

Heparin-coated shunts significantly reduce shunt-related mortality versus non-heparin-coated shunts.¹

GORE® PROPATEN® Vascular Graft configured for Pediatric Shunt Features CBAS® Heparin Surface, a coating demonstrated to provide lasting thromboresistance.²⁻⁶

Outcomes of a recent retrospective study comparing heparin-coated grafts with non-heparin-coated grafts utilized for conduits in systemic-to-pulmonary shunts in neonates and infants.¹

Outcomes	Non-heparin-coated (n = 73)	Heparin-coated (n = 69)	P-value
Mortality	14 (19.2%)	3 (4.3%)	0.006
Shunt-related mortality	12 (16.4%)	2 (2.9%)	0.007
Shunt occlusion/ Thrombosis	12 (16.4%)	2 (2.9%)	0.007

Together, improving life



GORE® PROPATEN® Vascular Graft Configured for Pediatric Shunt

Catalogue number	Internal diameter (mm)	Standard length (cm)
HPT030005	3	5
HPT030010	3	10
HPT030015	3	15
HPT350005	3.5	5
HPT350010	3.5	10
HPT350015	3.5	15
HPT040005	4	5
HPT040010	4	10
HPT040015	4	15
HPT050005	5	5
HPT050010	5	10
HPT050015	5	15
HPT060015	6	15

Ask your Gore Associate for inventory management of GORE® PROPATEN® Vascular Graft configured for Pediatric Shunt.

References

1. Ashfaq A, Soroya MS, Iyengar A, Federman M, Reemtsen BL. Heparin-coated grafts reduce mortality in pediatric patients receiving systemic-to-pulmonary shunts. *Pediatric Cardiology* 2018;39(3):473-477.
2. Gore S, Andersson J, Biran R, Underwood C, Riesenfeld J. Heparin surfaces: impact of immobilization chemistry on hemocompatibility and protein adsorption. *Journal of Biomedical Materials Research Part B: Applied Biomaterials* 2014;102(8):1817-1824.
3. Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX® Vascular Graft performance by Carmeda® BioActive Surface heparin immobilization. *European Journal of Vascular & Endovascular Surgery* 2003;25(5):432-437.
4. Freeman J, Chen A, Weinberg RJ, Okada T, Chen C, Lin PH. Sustained thromboresistant bioactivity with reduced intimal hyperplasia of heparin-bonded PTFE Propaten Graft in a chronic canine femoral artery bypass model. *Annals of Vascular Surgery* 2018;49:295-303. <http://www.sciencedirect.com/science/article/pii/S0890509617310981>
5. Biran R, Pond D. Heparin coatings for improving blood compatibility of medical devices. *Advanced Drug Delivery Reviews* 2017;112:12-23. <https://www.sciencedirect.com/science/article/pii/S0169409X16303210>
6. Carmeda AB. Carmeda® BioActive Surface (also known as CBAS® Heparin Surface) Reference List. Upplands Väsby, Sweden: Carmeda AB; 2018. [Reference list]. MD166953

 Consult Instructions
for Use
eifu.goremedical.com

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx Only

Products listed may not be available in all markets.

CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc.

GORE, GORE-TEX, *Together, improving life*, PROPATEN and designs are trademarks of W. L. Gore & Associates.
© 2022 W. L. Gore & Associates GmbH 22761013-EN OCTOBER 2022

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 6733 2882 **Australia/New Zealand** 1800 680 424 **Europe** 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771

